Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?

Am J Hematol. 2006 Feb;81(2):110-4. doi: 10.1002/ajh.20475.

Abstract

We report two cases of Waldenström's macroglobulinemia with an unusual aggressive transformation following treatment with cladribine (2-chlorodeoxyadenosine, 2-CdA), a purine analogue. The first patient developed transformation to a diffuse large-cell non-Hodgkin lymphoma, while the second developed extensive extramedullary involvement. Both patients displayed rapid progression following transformation and were refractory to chemotherapy. Both patients were pretreated with multiple courses of prednisone and chlorambucil, and transformation occurred shortly after therapy with cladribine. We propose that immune suppression from alkylating agents and purine analogues may have contributed to the unusual progression, resulting in a dismal outcome.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Alkylating / adverse effects
  • Cell Transformation, Neoplastic / chemically induced*
  • Cell Transformation, Neoplastic / pathology
  • Cladribine / adverse effects*
  • Disease Progression
  • Fatal Outcome
  • Female
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Lymphoma, Large B-Cell, Diffuse / chemically induced
  • Male
  • Purine Nucleosides / adverse effects
  • Purine Nucleosides / therapeutic use
  • Waldenstrom Macroglobulinemia / drug therapy*
  • Waldenstrom Macroglobulinemia / pathology*

Substances

  • Antineoplastic Agents, Alkylating
  • Purine Nucleosides
  • Cladribine